Investigating how an anti-aging molecule can protect the retina in diabetic patients
Anti-Aging Molecule Sirt6 in Neuroprotection in Diabetic Retina
This study is looking at how a special molecule called Sirt6 might help protect the eyes of people with diabetes from damage that can lead to vision loss, with the goal of finding new ways to keep your eyesight healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-11092848 on NIH RePORTER |
What this research studies
This research focuses on diabetic retinopathy, a leading cause of blindness in working-age adults, and aims to understand how the anti-aging molecule Sirt6 can protect retinal neurons from damage. The study will explore the mechanisms behind retinal ganglion cell injury and axonal degeneration in diabetes, which are critical to vision loss. By identifying novel strategies to limit this injury, the research seeks to develop new treatments that preserve vision in diabetic patients. The approach includes both animal models and patient studies to gather comprehensive data on the effects of Sirt6 in the retina.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with diabetic retinopathy who are at risk of vision loss.
Not a fit: Patients without diabetes or those who do not have diabetic retinopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent vision loss in diabetic patients by protecting retinal neurons.
How similar studies have performed: While there have been studies on the role of Sirt6 in other conditions, this specific application in diabetic retinopathy is relatively novel and untested.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Zhang, Wenbo — University of Texas Med Br Galveston
- Study coordinator: Zhang, Wenbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.